tumor targeting Articles
-
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity CD1d can be expressed by several hematologic malignancies Bispecific Vγ9Vδ2-T cell engager Unique ability to also trigger type 1 natural killer T (NKT) ...
-
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
A population of NK cells expressing the activating receptor NKG2C and the maturation marker CD57 expands in response to human CMV (HCMV) infection. CD3–CD56dimCD57+NKG2C+ NK cells are similar to CD8+ memory T cells with rapid and robust effector function upon restimulation, persistence, and epigenetic remodeling of the IFNG locus. Chronic antigen stimulation drives CD8+ memory T cell ...
-
MK-4101
MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma. target:SMO In vivo: MK-4101 was highly efficacious against primary medulloblastoma and BCC developing in the cerebellum and skin of Ptch1+/- mice. In vitro: MK-4101 induce deregulation of cell cycle and block of DNA replication in tumors. MK-4101 targets the Hh pathway in ...
-
Tumor Glycan-Targeted Therapy
Glycosylation is a sophisticated type of post-translational modification that impacts over 50% of cellular proteins and is a critical regulator of many eukaryotic processes. Aberrant glycosylation is a common hallmark of many malignancies and is important at all stages of tumor growth. Glycosylation regulates a range of physiopathological processes, including cell-cell adhesion, cell-matrix ...
-
A Raman-based endoscopic strategy for multiplexed molecular imaging
Endoscopic imaging is an invaluable diagnostic tool allowing minimally invasive access to tissues deep within the body. It has played a key role in screening colon cancer and is credited with preventing deaths through the detection and removal of precancerous polyps. However, conventional white-light endoscopy offers physicians structural information without the biochemical information that would ...
-
New Technology of PROTACs
Most of the drugs currently in clinical use are based on small molecules and use the "occupancy-driven" mode of action to inhibit the function of proteins and play a role in the treatment of diseases. Different from traditional small molecule inhibitors and antagonists, protein degradation technology has developed rapidly in recent years because of its ability to induce the degradation of ...
-
Challenges in Small Molecule Targeted Drug Development
The classical mode of action of small molecule drugs is "occupancy-driven". Since the FDA approved the first oral small molecule targeted therapy for tumors-tamoxifen targeting the estrogen receptor (ER)-in 1977 for the treatment of breast cancer, small molecule drug development has typically focused on screening for high-affinity inhibitors. Small molecule inhibitors can bind to the active sites ...
By BOC Sciences
-
ZAP Surgical Announces First Facility on the East Coast Initiates Patient Treatment Using New Non-Invasive Brain Tumor Therapy
ZAP Surgical Systems, Inc. today announced ZAP-X® Gyroscopic Radiosurgery® patient treatments have commenced at MedStar Georgetown Cancer Institute at MedStar Southern Maryland Hospital Center in Clinton, MD. For many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) has proven to be an effective treatment with outcomes equivalent to invasive surgical procedures. ...
-
Cell-Penetrating Peptides: Features, Mechanisms, Applications
Cell-penetrating peptides (CPPs) refer to water-soluble, partly hydrophobic, and/or polybasic short peptides that are fewer than 30 amino acids in size. Different types of CPPs like chimeric peptides and hydrophobic peptides have different lengths, charges, solubility, and hydrophobicity. At current, cell-penetrating peptides are often classified in line with their characteristics, including ...
-
Shining a Light on Drug Delivery: The Rise of Fluorescent Liposomes
Imagine tiny spheres, smaller than a red blood cell, glowing as they navigate the labyrinthine corridors of the human body. These aren't fireflies, they're fluorescent liposomes, a cutting-edge tool in the world of drug delivery and biomedical research. What are liposomes? Liposomes are microscopic bubbles made from phospholipids, the same fatty molecules that make up cell membranes. These ...
-
B7-H3: Broad Prospects of Emerging Tumor Immunotherapy Targets
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing favorable therapeutic efficacy and safety ...
-
Ozette’s computationally-driven analysis aids advancement of cancer drug development - Case study
Summary Inflammation is a hallmark of the tumor microenvironment and an area of active investigation. To better understand how tumor inflammation differs from general inflammation, such as in gum disease, Drs. Prilic, Mair, and Erikson employed novel methods, which included high parameter flow cytometry and Ozette’s foundational technology–full annotation using ...
-
Drug-Loaded Liposomes: Tiny Spheres with Big Potential
Imagine tiny bubbles, smaller than a red blood cell, carrying powerful medicines directly to diseased cells. This isn't science fiction, it's the cutting edge of drug delivery with drug-loaded liposomes. What are liposomes? Liposomes are microscopic spheres made from phospholipids, the same fatty molecules that make up cell membranes. These phospholipids naturally arrange themselves in ...
-
Antibody-Drug Conjugates: New Strategies of ADC Payloads
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal antibodies, that the era of ADC drug development truly began. Driven by increasingly mature technology, ADC drugs have gone through three iterations (Fig. 1). Although ADCs have gone through three iterations, current ...
By BOC Sciences
-
A Novel Potential Target for CAR-T Cell Therapy in Human Solid Tumors Discovered
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
-
Targeted Therapy of Intracellular Oncoproteins by Peptide-centered CAR T Cells
Researchers at the Children's Hospital of Philadelphia (CHOP) have made a breakthrough in the treatment of aggressive solid cancers, and they have developed a new cancer treatment that targets proteins within tumor cells that are essential for tumor growth and survival, but this has not been possible before. Using the power of large data and advanced computational methods, researchers can ...
-
Three generations of ADC Nearly a decade of development-PIII
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
-
Bispecific Antibodies and Bispecific Antibody ADCs
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. Bispecific antibody conjugates (BsAb ADCs) are one of the emerging new technologies. The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other ...
By BOC Sciences
-
The Role of Exosome RNA in Cancer
The Relationship Between Exosomes and Cancer Exosomes are nanoscale vesicles derived from intracellular lysosomes that shuttle a variety of biomolecules, such as nucleic acids, proteins, lipids, amino acids and metabolites, and play a key role in regulating intercellular communication. Exosomes can be secreted by almost all types of cells, including immune cells, blood cells, neuronal cells, ...
By CD Genomics
-
Comparison of Flexible Silicone Bolus to 3D Printed Rigid Bolus - Case Study
This case study illustrates designing and fabricating silicone bolus using the Adaptiiv software solution. This flexible silicone bolus fabrication process was then compared to the fabrication process of a rigid 3D printed bolus to determine whether it yielded comparable or improved plan metrics for treating an inner canthus ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you